Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

BACKGROUND: MET exon 14 skipping is an oncogenic driver occurring in 3–4% of non-small cell lung cancer (NSCLC). The MET inhibitor tepotinib has demonstrated clinical efficacy in patients with MET exon 14 skipping NSCLC. Here, we present data from Japanese patients in the Phase II VISION study, eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Hiroshi, Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Sakamoto, Tomohiro, Kumagai, Toru, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Tanaka, Hiroshi, Chikamori, Kenichi, Shinagawa, Naofumi, Takeoka, Hiroaki, Bruns, Rolf, Straub, Josef, Schumacher, Karl Maria, Paik, Paul K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326385/
https://www.ncbi.nlm.nih.gov/pubmed/34037224
http://dx.doi.org/10.1093/jjco/hyab072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326385/
https://www.ncbi.nlm.nih.gov/pubmed/34037224
http://dx.doi.org/10.1093/jjco/hyab072

Ejemplares similares